Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 531-538

  Pereira, Michelly C ^a,b   De Bessa Garcia, Simone A ^a,b   Burikhanov, Ravshan ^c   Pavanelli, Ana Carolina ^a,b   Antunes, Lourival ^a,b   Rangnekar, Vivek M ^c   Nagai, Maria Aparecida ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratory of Molecular Genetics Center for Translational Research in Oncology   (Brazil)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Breast cancer; Docetaxel; Par 4; Proliferation; Survival

Indexed keywords

ACRIDINE ORANGE; APOPTOSIS REGULATORY PROTEIN; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTATE APOPTOSIS RESPONSE 4; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; DOWN REGULATION; DRUG SENSITIVITY; EXPRESSION VECTOR; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAXOIDS; TRANSFECTION;

EID: 84879654301     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1983     Document Type: Article

References (44)

1. Macciò A and Madeddu C: Obesity, inflammation and post-menopausal breast cancer: therapeutic implications. TSWJ 11: 2020-2036, 2011.
2. Parton M, Dowsett M and Smith I: Studies of apoptosis in breast cancer. BMJ 322: 1528-1532, 2001. (Pubitemid 32588351)
3. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
4. Makin G and Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res 301: 143-152, 2000. (Pubitemid 30459861)
5. Sells SF, Wood Jr DP, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S and Rangnekar VM: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5: 457-466, 1994. (Pubitemid 24251397)
6. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, Gillis D, Liu G, Nair P, Monnig S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DP Jr, McRoberts JW, Shi Y and Rangnekar VM: Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17: 3823-3832, 1997. (Pubitemid 27281857)
7. El-Guendy N and Rangnekar VM: Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 283: 51-66, 2003. (Pubitemid 36259895)
8. Goswami A, Ranganathan P and Rangnekar VM: The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66: 2889-2892, 2006.
9. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R and Rangnekar VM: Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23: 5516-5525, 2003. (Pubitemid 36951320)
10. Zhao Y, Burikhanov R, Qiu S, Lele SM, Jennings CD, Bondada S, Bryson S and Rangnekar VM: Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 67: 9276-9285, 2007.
11. Gurumurthy S, Goswami A, Vasudevan KM and Rangnekar VM: Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25: 1146-1161, 2005. (Pubitemid 40165820)
12. Kögel D, Reimertz C, Mech P, Poppe M, Frühwald MC, Engemann H, Scheidtmann KH and Prehn JH: Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: requirement of the mitochondrial apoptosis pathway. Br J Cancer 85: 1801-1808, 2001.
13. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M and Palacios J: Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 67: 1927-1934, 2007. (Pubitemid 46424208)
14. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH and Rangnekar VM: Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18: 1205-1208, 1999. (Pubitemid 29085993)
15. Nagai MA, Gerhard R, Salaorni S, Fregnani JH, Nonogaki S, Netto MM and Soares FA: Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 37: 41-49, 2010.
16. García-Cao I, Duran A, Collado M, Carrascosa MJ, Martín-Caballero J, Flores JM, Diaz-Meco MT, Moscat J and Serrano M: Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 6: 577-583, 2005.
17. Chakraborty M, Qiu SG, Vasudevan KM and Rangnekar VM: Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61: 7255-7263, 2001. (Pubitemid 32946523)
18. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R and Lopez-Berestein G: Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278: 19995-20005, 2003. (Pubitemid 36799192)
19. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR and Rangnekar VM: The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138: 377-388, 2009.
20. Zhao Y, Burikhanov R, Brandon J, Qiu S, Shelton BJ, Spear B, Bondada S, Bryson S and Rangnekar VM: Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biol Ther 12: 152-157, 2011.
21. Franchitto A, Torrice A, Semeraro R, Napoli C, Nuzzo G, Giuliante F, Alpini G, Carpino G, Berloco PB, Izzo L, Bolognese A, Onori P, Renzi A, Cantafora A, Gaudio E and Alvaro D: Prostate apoptosis response-4 is expressed in normal cholangiocytes is down-regulated in human cholangiocarcinoma and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically. Am J Pathol 177: 1779-1790, 2010.
22. Casolari DA, Pereira MC, de Bessa Garcia SA and Nagai MA: Insulin-like growth factor-1 and 17â-estradiol down-regulate prostate apoptosis response-4 expression in MCF-7 breast cancer cells. Int J Mol Med 28: 337-342, 2011.
23. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
24. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM and Shi Y: A novel repressor, par-4 modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956, 1996. (Pubitemid 26389754)
25. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH and Rangnekar VM: Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18: 623-631, 1999. (Pubitemid 29080319)
26. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS and Weidmann E: In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 62: 1768-1775, 2002. (Pubitemid 34408501)
27. Chan SL, Tammariello SP, Estus S and Mattson MP: Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J Neurochem 73: 502-512, 1999. (Pubitemid 29339822)
28. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001. (Pubitemid 32458157)
29. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H and Okumura K: Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 95: 3537-3542, 1998.
30. Gurumurthy S and Rangnekar VM: Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem 91: 504-512, 2004.
31. Shrestha-Bhattarai T and Rangnekar VM: Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29: 3873-3880, 2010.
32. Degterev A and Yuan J: Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9: 378-390, 2008. (Pubitemid 351574200)
33. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
34. Simstein R, Burow M, Parker A, Weldon C and Beckman B: Apoptosis, chemoresistance and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 228: 995-1003, 2003. (Pubitemid 37222167)
35. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nuñez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G and Kroemer G: Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19: 107-120, 2012.
36. MacLean MA, Scott BE, Deziel BA, Nunnelley MC, Liberty AM, Gottschall-Pass KT, Neto CC and Hurta RA: North American cranberry (Vaccinium macrocarpon) stimulates apoptotic pathways in DU145 human prostate cancer cells in vitro. Nutr Cancer 63: 109-120, 2011.
37. Boehrer S, Kukoc-Zivojnov N, Nowak D, Bergmann M, Baum C, Puccetti E, Weidmann E, Hoelzer D, Mitrou PS and Chow KU: Upon drug-induced apoptosis expression of prostate-apoptosis-response-gene-4 promotes cleavage of caspase-8, bid and mitochondrial release of cytochrome c. Hematology 9: 425-431, 2004. (Pubitemid 40123595)
38. Chendil D, Das A, Dey S, Mohiuddin M and Ahmed MM: Par-4, a pro-apoptotic gene inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 1: 152-160, 2002.
39. Crown J and O'Leary M: The taxanes: an update. Lancet 355: 1176-1178, 2000. (Pubitemid 30172946)
40. Morse DL, Gray H, Payne CM and Gillies RJ: Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4: 1495-1504, 2005. (Pubitemid 41556431)
41. Hernández-Vargas H, Palacios J and Moreno-Bueno G: Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26: 2902-2913, 2007.
42. Kline CL, Shanmugavelandy SS, Kester M and Irby RB: Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 8: 1831-1837, 2009.
43. Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E and Chow KU: In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Biochem Pharm 68: 85-93, 2004. (Pubitemid 38746544)
44. Lee TJ, Lee JT, Kim SH, Choi YH, Song KS, Park JW and Kwon TK: Overexpression of Par-4 enhances thapsigargin-induced apoptosis via down-regulation of XIAP and inactivation of Akt in human renal cancer cells. J Cell Biochem 103: 358-368, 2008. de São Paulo e Tecnológico